United States · FDA National Drug Code directory
HEPLISAV-B
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 43528-003_4b308f87-c35b-9d96-e063-6294a90aff8e
- Product NDC
- 43528-003
- Form
- INJECTION, SOLUTION
- Composition / generic term
- Hepatitis B Vaccine (Recombinant) Adjuvanted
- Labeler
- Dynavax Technologies Corporation
- Marketing category
- BLA
- Marketing start / end (source format)
- 20180101
- Source listing expiry
- 20271231
Source-listed ingredients
- HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN — 20 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 5 SYRINGE in 1 CARTON (43528-003-05) / .5 mL in 1 SYRINGE (43528-003-01) · 43528-003-05
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →